"Science and Technology Innovation Board**" on February 6After Novo Nordisk Semaglutide was approved for listing in China, it recently became a shareA number of companies have successively disclosed the clinical trial trends of semaglutide injection
On February 5, Livzon Group announced that its holding subsidiary, New Beijiang Pharmaceutical, received the "Drug Clinical Trial Approval Notice" approved and issued by the State Food and Drug Administration, approving semaglutide injection to carry out clinical trials for weight management indications in accordance with the technical requirements of biosimilars.
Hanyu Pharmaceutical announced on February 1 that it had received the "Notice of Acceptance" approved by the State Food and Drug Administration for the issuance of the clinical trial application for semaglutide injection. Indications for this drug: As an adjunct to a low-calorie diet and increased physical activity**, for weight management in patients who are obese or overweight with at least 1 weight-related comorbidity**.
Huadong Medicine also revealed on the interactive platform on January 31 that the company's semaglutide injection diabetes indication has completed the enrollment of phase 3 clinical subjects, and is expected to complete phase 3 clinical trials in 2024.
Looking overseas, yesterday Novo Nordisk's major shareholder Novo Holdings announced that it would acquire Biopharmaceutical contract manufacturer Catalent in an all-cash transaction, with a total corporate value of $16.5 billion plus debt. As part of the deal, Novo Nordisk will acquire three Catalent's bottling plants from Novo Holdings for an upfront payment of US$11 billionThe move will help increase production capacity of its best-selling ** drugs, Wegovy and Ozempic, both semaglutide products
Affected by this news, Novo Nordisk U.S. stocks rose 4% last night; Eli Lilly, another ** drug leader, also rose 577%，Shares of both companies have reached record highs
Today's A-share ** drug concept stocks also rose sharply. As of **, Borui Pharmaceutical rose 16%, Puli Pharmaceutical rose more than 11%, and Jianxingyuan, Huadong Medicine, Livzon Group, etc. rose sharply.
At the end of 2022, due to the good efficacy of semaglutide and the publicity of celebrities such as Musk, it has become a popular "miracle drug".
Nowadays, the weight loss market is expanding rapidly, and the Prospective Industry Research Institute predicts that the market size of China's weight loss drugs will reach 15.3 billion yuan in 2030.
Founder**February 2** pointed out that the enthusiasm for the research and development of GLP-1 products represented by semaglutide is still highThe availability of medications and the need for long-term medication to avoid body weight** are major concerns
At present, many domestic companies are actively carrying out research on innovative drugs and generic drugs targeting GLP-1.
Among them, Hengrui Pharmaceutical has laid out oral small molecule GLP-1 receptor agonists and GLP-1 GIP dual-target agonists; Innovent met the primary endpoint and all key secondary endpoints in the first-in-class clinical study of Innovent GLP-1R GCGR dual agonist Mastotide in overweight or obese** subjects in China (GLORY-1); The GLP-1 GIP receptor dual agonist independently developed by Borui Pharmaceutical has biological effects such as blood sugar control, weight loss and NASH, and has the potential for a variety of metabolic diseases.
In terms of generic drugs, Qilu Pharmaceutical, Chia Tai Tianqing, Huadong Pharmaceutical, Federal Pharmaceutical, Livzon Pharmaceutical, Zhifei Biotechnology, etc. are all in the phase II clinical stage.
As for other links in the domestic peptide industry chain, there are also a number of listed companies that have laid out related businesses. There are 4 domestic API filing enterprises for semaglutide: Tianji Biotechnology, Nuotai Biotechnology, Paipeptide Biotechnology, and Jianxiang Biotechnology, all of which have been accepted; The companies that have been registered in the United States include 14 Chinese pharmaceutical companies, including Hanyu Pharmaceutical, Gloria Young, and Shengnuo.